ПРЕПРИНТ
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
Частота системных микозов значительно возросла за последние два десятилетия. Такой рост тесно связан с повышением числа иммунокомпрометирующих субъектов, обусловленным иммунотерапией онкологических и гематологических заболеваний, реципиентов трансплантатов, ВИЧ-инфекцией, лечением глюкокортикоидами. Кроме того, такие факторы, как старение населения мира и продолжительное использование антимикробных препаратов приводит к выраженному увеличению инвазивных микозов человека. Госпитализированные с COVID-19 пациенты, особенно тяжело больные или иммунокопромиссные, имеют повышенный риск развития коинфекций с инвазивными системными микозами. Это связано не только с клинической ситуацией и необходимостью инвазивной помощи, но также иммунной перестройкой, вызванной SARS-CoV-2, и используемым лечением (кортикостероиды, некоторые интерфероны, циклоспорин, ингибиторы ИЛ-6 и ИЛ-1). По-видимому у пациентов с COVID-19 наиболее часто развиваются легочный аспергиллез, мукормикоз, кандидоз и пневмоцистные пневмонии.
Топорков А. В., Липницкий А. В., Половец Н. В., Викторов Д. В., Суркова Р. С. 2021. ИНВАЗИВНЫЕ МИКОЗЫ - КОИНФЕКЦИИ COVID-19. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111961
1. Lescure F.X., Bouadma L., Nguyen D. et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020. Vol.20. P.697–706. doi:10.1016/S1473-3099(20)30200-0.
2. Alanio A., Dellière S., Fodil S. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020. Vol.8. P.e48–9. doi:10.1016/S2213-2600(20)30237-X.
3. Koehler P., Cornely O.A., Böttiger B.W. et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020. Vol.63. P.528–34. doi:10.1111/myc.13096.
4. Blaize M., Mayaux J., Nabet C. et al. Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient. Emerg Infect Dis. 2020. Vol.26. P.1636–7. doi:10.3201/eid2607.201603.
5. Prattes J., Valentin T., Hoenigl M. et al. Invasive pulmonary aspergillosis complicating COVID-19 in the ICU - A case report. Med Mycol Case Rep. 2020. Epub ahead of print. doi:10.1016/j.mmcr.2020.05.001.
6. Antinori S., Rech R., Galimberti L. et al. Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge. Travel Med Infect Dis. 2020. Vol.101752. Epub ahead of print. doi:10.1016/j.tmaid.2020.101752.
7. Rutsaert L., Steinfort N., Van Hunsel T. et al. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care. 2020. Vol.10. P.71. doi:10.1186/s13613-020-00686-4.
8. Wang J., Yang Q., Zhang P. et al. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020. Vol.24. P.299. doi:10.1186/s13054-020-03046-7.
9. Meijer E.F., Dofferhoff A.S., Hoiting O. et al. Azole-resistant COVID-19-associated pulmonary aspergillosis in an immunocompetent host: a case report. J Fungi (Basel). 2020. Vol.6. P.79. doi:10.3390/jof6020079.
10. Ghelfenstein-Ferreira T., Saade A., Alanio A. et al. Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU - A case report. Med Mycol Case Rep. 2020. Epub ahead of print. doi:10.1016/j.mmcr.2020.06.006.
11. Santana M.F., Pivoto G., Alexandre M.A.A. et al. Confirmed invasive pulmonary Aspergillosis and COVID-19: the value of postmortem findings to support antemortem management. Rev Soc Bras Med Trop. 2020. Vol.53. P.e20200401. doi:10.1590/0037-8682-0401-2020.
12. Bartoletti M., Pascale R., Cricca M. et al. PREDICO study group. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis. 2020. Vol. ciaa1065; Epub ahead of print. doi:10.1093/cid/ciaa1065.
13. Nasir N., Farooqi J., Mahmood S.F. et al. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. Mycoses. 2020. Vol.63. P.766–70. doi:10.1111/myc.13135.
14. Van Biesen S., Kwa D., Bosman R.J. et al. Detection of invasive pulmonary aspergillosis in COVID-19 with non-directed bronchioalveolar lavage. Am J Respir Crit Car Med. 2020. [Epub ahead of print].
15. Flikweert A.W., Grootenboers M.J.J.H., Yick D.C.Y. et al. Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series. J Crit Care. 2020. Vol.59. P.149–55. doi:10.1016/j.jcrc.2020.07.002.
16. Falces-Romero I., Ruiz-Bastián M., Díaz-Pollán B. et al. SARS-CoV-2 Working Group. Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish Tertiary Care Hospital. Mycoses. 2020. Vol.63. P.1144–8. doi:10.1111/myc.13155.
17. Helleberg M., Steensen M., Arendrup M.C. Invasive aspergillosis in patients with severe COVID-19 pneumonia. Clin Microbiol Infect. 2020. Vol.S1198-743X(20)30474-2. doi:10.1016/j.cmi.2020.07.047.
18. White P.L., Dhillon R., Cordey A. et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis. 2020. Vol.ciaa1298. doi:10.1093/cid/ciaa1298.
19. Delliere S., Dudoignon E., Fodil S. et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clin Microbiol Infect. 2020. Vol.27(5). P.790.e1-790.e5. doi: 10.1016/j.cmi.2020.12.005.
20. Lamoth F., Glampedakis E., Boillat-Blanco N. et al. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin Microbiol Infect. 2020. Vol.S1198-743X(20)30412-2.
21. Meijer E.F., Dofferhoff A.S., Hoiting O. et al. COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series. Mycoses. 2021. Vol.64(4). P.457-464. doi: 10.1111/myc.13254.
22. Fekkar A., Lampros A., Mayaux J. et al. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. Am J Respir Crit Care Med. 2021. Vol.203(3). P.307-317. doi: 10.1164/rccm.202009-3400OC.
23. Netea M.G., Giamarellos-Bourboulis E.J., Domínguez-Andrés J. et al. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell. 2020. Vol.181(5). P.969–977. doi: 10.1016/j.cell.2020.04.042.
24. Mitaka H., Kuno T., Takagi H. et al. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis. Mycoses. 2021. doi: 10.1111/myc.13292.
25. Van Arkel A.L.E., Rijpstra T.A., Belderbos H.N.A. et al. COVID-19-associated pulmonary aspergillosis. Am J Respir Crit Care Med. 2020. https://doi.org/10/1164/reem.202004-10381e.
26. Blot S.I., Taccone F.S., Van den Abeele A.M. et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012. Vol.186(1). P.56–64. doi: 10.1164/rccm.201111-1978OC.
27. Patterson T.F., Thompson G.R., 3rd, Denning D.W. et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016. Vol.63(4). P:e1–e60. doi: 10.1093/cid/ciw326.
28. Шагдилеева Е.В., Зайцева Е.А., Шадривова О.В. и др. Хронический аспергиллез легких у пациентов после перенесенной COVID-19: описание клинических случаев и обзор литературы. Проблемы медицинской микологии. 2020. Т.22. №4. С.8-14.
29. Koehler P., Bassetti M., Chakrabarti A., et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2020. Vol.S1473-3099 (20) 30847-1. doi: 10.1016/S1473-3099(20)30847-1.
30. Prakash H., Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021. Vol.9(3). P.523. doi: 10.3390/microorganisms9030523.
31. Prakash H., Ghosh A.K., Rudramurthy S.M. et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med. Mycol. 2019. Vol.57. P.395–402. doi: 10.1093/mmy/myy060.
32. Patel A., Kaur H., Xess I. et al. A multi-centre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin. Microbiol. Infect. 2020. Vol.26. P.944.e9–944.e15. doi: 10.1016/j.cmi.2019.11.021.
33. Jeong W., Keighley C., Wolfe R. et al. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 2019. Vol.25. P.26–34. doi: 10.1016/j.cmi.2018.07.011.
34. Song G., Liang G., Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia. 2020. P.1–8. doi: 10.1007/s11046-020-00462-9.
35. Skiada A., Lass-Floerl C., Klimko N. et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018. Vol.56(suppl 1). P.93–101. doi: 10.1093/mmy/myx101.
36. Dadwal S.S., Kontoyiannis D.P. Recent advances in the molecular diagnosis of mucormycosis. Expert Rev Mol Diagn. 2018. Vol.18(10). P.845–854. doi: 10.1080/14737159.2018.1522250.
37. Sen M., Lahane S., Lahane T. P. et al. Mucor in Viral Land: A tale of two pathogens. Indian J Ophthalmol. 2021. Vol.69(2). P.244-252. doi: 10.4103/ijo.IJO_3774_20.
38. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021. Vol.42. P.264.e5-264.e8. doi: 10.1016/j.ajem.2020.09.032.
39. Mekonnen Z.K., Ashraf D.C., Jankowski T. et al. Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome. Ophthalmic Plast Reconstr Surg. 2021. Vol.37(2). P.e40-e80. doi: 10.1097/IOP.0000000000001889.
40. Garg D., Muthu V., Sehgal I. S. et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021. P.1–10. doi: 10.1007/s11046-021-00528-2.
41. Hanley B., Naresh K.N., Roufosse C. et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020. Vol.1(6). P.e245–e253. doi: 10.1016/S2666-5247(20)30115-4.
42. Monte Junior E.S.D., Santos M., Ribeiro I.B. et al. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. Clin Endosc. 2020. Vol.53(6). P.746–749. doi: 10.5946/ce.2020.180.
43. Pasero D., Sanna S., Liperi C. et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020. doi:10.1007/s15010-020-01561-x.
44. Apicella M., Campopiano M.C., Mantuano M. et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020. Vol.8(9). P.782–792. doi: 10.1016/S2213-8587(20)30238-2.
45. Ibanez-Martinez E., Ruiz-Gaitan A., Peman-Garcia J. Update on the diagnosis of invasive fungal infection. Rev Esp Quimioter. 2017. Vol.30(Suppl 1). P.16–21.
46. Hage C.A., Carmona E.M., Epelbaum O. et al. Microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019. Vol.200(10). P.1326. doi: 10.1164/rccm.201906-1185ST.
47. Salehi M., Ahmadikia K., Badali H. et al. Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran. Mycopathologia. 2020. Vol.185(4). P.607-611. doi: 10.1007/s11046-020-00472-7.
48. Nucci M., Barreiros G., Guimares L. et al. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. Mycoses. 2021. Vol.64(2). P.152-156. doi: 10.1111/myc.13225.
49. Chowdhary A., Tarai B., Singh A. et al. Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April-July 2020. Emerg Infect Dis. 2020. Vol.26(11). P.2694-2696. doi: 10.3201/eid2611.203504.
50. Prestel C., Anderson E., Forsberg K. et al. Candida auris Outbreak in a COVID-19 Specialty Care Unit - Florida, July-August 2020. MMWR Morb Mortal Wkly Rep. 2021. Vol.70(2). P.56-57. doi: 10.15585/mmwr.mm7002e3.
51. Almeida J.N., Brandao I.B., Francisco E.C. et al. Axillary Digital Thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil. Mycoses. 2021. doi: 10.1111/myc.13320.
52. Macauley P., Epelbaum O. Epidemiology and Mycology of Candidaemia in non-oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysis and comparison between non-COVID-19 and COVID-19 cases. Mycoses. 2021. Vol.64(6). P.634-640. doi: 10.1111/myc.13258.
53. Bishburg E., Okoh A., Nagarakanti S.R. et al. Fungemia in COVID-19 ICU patients, a single medical center experience. J Med Virol. 2021. Vol.93(5). P.2810-2814. doi: 10.1002/jmv.26633.
54. Pappas P.G., Kauffman C.A., Andes D.R. et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016. Vol.62(4). Vol.e1–e50. doi: 10.1093/cid/civ933.
55. Antinori S., Bonazzetti C., Gubertini G. et al. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmun Rev. 2020. P.102564–102567. doi: 10.1016/j.autrev.2020.102564.
56. Peman J., Ruiz-Gaitan A., Garcia-Vidal C. et al. Fungal co-infection in COVID-19 patients: Should we be concerned? Rev Iberoam Micol. 2020. Vol.37(2). P.41-46. doi: 10.1016/j.riam.2020.07.001.
57. Kelly S., Waters L., Cevik M. et al. Pneumocystis pneumonia, a COVID-19 mimic, reminds us of the importance of HIV testing in COVID-19. Clin Med (Lond). 2020. Vol.20(6). P.590-592. doi: 10.7861/clinmed.2020-0565.
58. Jeican I.I., Inisca P., Gheban D. et al. COVID-19 and Pneumocystis jirovecii pulmonary coinfection - the first case confirmed through autopsy. Medicina (Kaunas). 2021. Vol.57(4). P.302. doi: 10.3390/medicina57040302.
59. Viceconte G., Buonomo A.R., Lanzardo A. et al. Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19. Infect Dis (Lond). 2021. Vol.53(5). P.382-385. doi: 10.1080/23744235.2021.1890331.
60. Nanjappa S.G., Heninger E., Wüthrich M. et al. Protective antifungal memory CD8 + T cells are maintained in the absence of CD4 + T cell help and cognate antigen in mice. J Clin Invest. 2012. doi: 10.1172/JCI58762.
61. Grifoni A., Weiskopf D., Ramirez S.I. et al.: Targets of T-cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020. Vol.181(7). P.1489–1501.e15.doi: 10.1016/j.cell.2020.05.015.
62. De Biasi S., Meschiari M., Gibellini L. et al.: Marked T-cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun 2020. Vol.11(1). P.1–17. doi: 10.1038/s41467-020-17292-4.
63. Zheng M., Gao Y., Wang G. et al.: Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020. Vol.17(5). P.533–5. doi: 10.1038/s41423-020-0402-2.
64. Krauth D.S., Jamros C.M., Rivard S.C. et al. Accelerated progression of disseminated coccidioidomycosis following SARS-CoV-2 infection: a case report. Mil Med. 2021. Vol.usab132. doi: 10.1093/milmed/usab132.
65. Brown J., Benedict K., Park B.J. et al. Coccidioidomycosis: epidemiology. Clin Epidemiol. 2013. Vol.5(1). P.185–97. doi: 10.2147/CLEP.S34434.
66. Chang C.C., Senining R., Kim J. et al. An acute pulmonary coccidioidomycosis coinfection in a patient presenting with multifocal pneumonia with covid-19. Journal of Investigative Medicine High Impact Case Reports. 2020. Vol. 8. P.1-3. doi: 10.1177/2324709620972244.
67. Messina F.A., Marin E., Caceres D.H. et al. Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV—A Case Report from Argentina and Literature Review. J. Fungi. 2020. Vol.6. P.275. doi: 10.3390/jof6040275.
68. Basso R.P., Poester V.R., Benelli J.L. et al. COVID-19-Associated Histoplasmosis in an AIDS Patient. Mycopathologia. 2020. Vol.186. P.109–112. doi: 10.1007/s11046-020-00505-1.
69. Bertolini M., Mutti M.F., Barletta J.A. et al. COVID-19 Associated with AIDS-Related Disseminated Histoplasmosis: A Case Report. Int. J. STD AIDS. 2020. Vol.31. P.1222–1224. doi: 10.1177/0956462420957518.
70. Wheat L.J., Azar M.M., Bahr N.C. et al. Histoplasmosis. Infect. Dis. Clin. N. Am. 2016. Vol.30. P.207–227. doi: 10.1016/j.idc.2015.10.009.
71. Azar M.M., Hage C.A. Clinical Perspectives in the Diagnosis and Management of Histoplasmosis. Clin. Chest. Med. 2017. Vol.38. P.403–415. doi: 10.1016/j.ccm.2017.04.004.
72. De Macedo P.M., Freitas A.D., Bartholo T.P. et al. Acute pulmonary histoplasmosis following covid-19: novel laboratorial methods aiding diagnosis. J Fungi (Basel). 2021. Vol.7(5). P.346. doi: 10.3390/jof7050346.
73. Martinez R. New Trends in Paracoccidioidomycosis epidemiology. J Fungi (Basel). 2017. Vol.3(1). P.1. doi: 10.3390/jof3010001.
74. Shikanai-Yasuda M.A., Mendes R.P., Colombo A.L. et al. Brazilian guidelines for the clinical management of paracoccidioidomycosis. Rev Soc Bras Med Trop. 2017. Vol.50(5). P.715–740. doi:10.1590/0037-8682-0230-2017.
75. de Macedo P.M., Almeida-Paes R., Freitas D.F. et al. Acute juvenile Paracoccidioidomycosis: A 9-year cohort study in the endemic area of Rio de Janeiro, Brazil. PLoS Negl Trop Dis. 2017. Vol.11(3). P.e0005500 doi:10.1371/journal.pntd.0005500.
76. Mendes R.P., Cavalcante R.S., Marques S.A. et al. Paracoccidioidomycosis: Current Perspectives from Brazil. Open Microbiol J. 2017. Vol.11. P.224–282. doi:10.2174/1874285801711010224.
77. de Macedo P.M., Freitas D.F.S., Varon A.G. et al. COVID-19 and acute juvenile paracoccidioidomycosis coinfection. PLoS Negl Trop Dis. 2020. Vol.14(8). P.e0008559. doi: 10.1371/journal.pntd.0008559.
78. Mehta P., McAuley D.F., Brown M. et al. Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020. P.395(10229). P.1033–1034. doi:10.1016/S0140-6736(20)30628-0.
79. Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. Epub 2020 Apr 6. doi:10.1038/s41577-020-0305-6.
80. Ventoulis I., Sarmourli T., Amoiridou P. et al. Bloodstream infection by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of Saccharomyces in the ICU. J Fungi. 2020. Vol.6. P.98. doi: 10.3390/jof6030098.
